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Alzheimer’s disease (AD) is the most common neurodegenerative disorder associated 
with aging. There are currently no effective treatments for AD. Bazhu decoction (BZD), 
a traditional Chinese medicine (TCM) formula, has been employed clinically to alleviate 
AD. However, the underlying molecular mechanisms are still unclear. Here we found that 
middle- and high-doses of BZD ameliorated the behavioral aspects of 5xFAD transgenic 
mice in elevated plus maze, Y maze and Morris water maze tests. Moreover, BZD reduced 
the protein levels of BACE1 and PS1, resulting in a reduction of Aβ plaques. We also 
identified a beneficial effect of BZD on oxidative stress by attenuating MDA levels and SOD 
activity in the brains of 5xFAD mice. Together, these results indicate that BZD produces 
a dose-dependent positive effect on 5xFAD transgenic mouse model by decreasing APP 
processing and Aβ plaques, and by ameliorating oxidative damage. BZD may play a 
protective role in the cognitive and anxiety impairments and may be a complementary 
therapeutic option for AD.
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INTRODUCTION
Alzheimer’s disease (AD), the most common cause of dementia in the elderly, is an age-related 
neurodegenerative disease characterized by progressive loss of memory, cognitive dysfunction, 
and other executive deficits (Mattson, 2004; Stokin et al., 2005). According to the World Alzheimer 
Report 2018 (Patterson, 2018), 50 million people are currently affected by AD, and this number 
is expected to increase to more than 152 million by 2050. AD, therefore places a huge economic 
burden on society and on many families.
Pathologically, the classic hallmarks of AD include the accumulation of extracellular senile 
plaques constituted of aggregated β-amyloid (Aβ), intracellular neurofibrillary tangles (NFTs), and 
synapse loss (Alzheimer et al., 1995). Since Aβ is one of the primary components of amyloid plaques 
in the brains of patients with AD, hypotheses have been proposed regarding the key contribution 
of Aβ in the pathological alterations and cognitive impairment in AD (Hardy and Allsop, 1991; 
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Hardy  and Higgins, 1992). Multiple lines of evidence show 
that Aβ accumulation leads to neurotoxicity and memory 
deterioration. Aβ is generated from the proteolytic processing 
of amyloid precursor protein (APP) by β-secretase (BACE1) 
and γ-secretase (Checler, 1995; Zhang et al., 2014). Presenilin-1 
(PS1) functions as the catalytic subunit of γ-secretase (Zhang 
et al., 2014).
Previous studies have suggested that Aβ plaques can 
induce activation of glial cells including astrocytes and 
microglia, leading to inflammation and oxidative stress (Lu et 
al., 2009; Li et al., 2011; Zhou et al., 2014). This may hinder 
neurotransmitter release, induce neuronal apoptosis and/or 
neuronal degeneration, and eventually contribute to cognitive 
impairment in AD. Malondialdehyde (MDA), a metabolite of 
lipid peroxidation, reflects the levels of free radicals and cellular 
damage (higher lipid peroxidation correlates to higher levels 
of MDA) (Giera et  al., 2012). Superoxide dismutase (SOD) 
is a critical antioxidant, which can effectively eliminate the 
superoxide anion, protecting against neuronal toxicity (Batinic-
Haberle et al., 2014).
Despite its high impact, the drugs (including donepezil 
HCl, rivastigmine, galanthamine, and memantine) commonly 
prescribed to treat AD patients merely relieve symptoms 
temporarily instead of decelerating the progression of disease 
(Wang et al., 2014; Cao et al., 2018). Preliminary clinical 
and preclinical studies have suggested that some traditional 
Chinese medicines (TCM) are beneficial to the prevention 
and control of AD. For instance, Fumanjian, a classic 
Chinese herbal formula, could ameliorate the impairment 
of spatial learning and memory by modulating the apoptotic 
signaling pathway in the hippocampus of rats with Aβ1–40-
induced AD (Hu et  al., 2014). TCM Shen-Zhi-Ling oral 
liquid not only improved behavioral and neuropsychological 
symptoms of dementia in AD patients, but also ameliorated 
memory impairment in AD mice by modulating the HO-1/
BVR system (Xing et al., 2017). In addition, components of 
certain herbal formulations may constitute an alternative 
complementary approach to alleviate symptoms and delay the 
progression of AD (Jesky and Hailong, 2011; May et al., 2016). 
Oral administration of alpha-asarone, an active substance of 
Rhizoma Acori Tatarinowii (Shichangpu), improved working 
spatial memory in AD-like preclinical models (Limon et al., 
2009). In the same study, the authors also suggested that this 
effect may be attributed to the protection of neuronal cells 
from oxidative stress, owing to decreases in NO production 
and Aβ-neurotoxicity. Therefore, TCM may represent an 
effective therapeutic option for AD, and warrants further 
investigation.
Bazhu decoction (BZD) is a formula of TCM that includes 
Radix Morindae Officinalis (Bajitian), Fructus Corni 
(Shanzhuyu), Pheretima (Dilong), Rhizoma Acori Tatarinowii 
(Shichangpu) and Arisaema cum Bile (Dannanxing). These 
compounds may enhance memory and ameliorate cognitive 
dysfunction in patients with AD (Li et al., 2016; Peng and 
Huang, 2017). Moreover, previous studies have suggested that 
water extracts from the respective herbs contained in BZD 
significantly improve learning and memory in AD-like animals 
via antioxidation, scavenging free radicals, neuroprotection, 
immunity enhancement, and by reducing the deposition of 
senile plaques (Jin et al., 2009; Wen and Chen, 2009; Li et al., 
2013; Wang et al., 2013). Nevertheless, the mechanisms by 
which BZD may ameliorate AD remain elusive. In this study, 
we sought to explore the effect of BZD in 5xFAD mice (Oakley 
et al., 2006), a recognized transgenic mouse model of AD, by 
investigating the biological mechanisms underlying its potential 
therapeutic effect.
MATeRIAls AND MeThODs
experimental Animals
5xFAD transgenic mice and wild-type littermates (50% 
females; weight: 25 ± 3 g; age: 3 months) were from the 
Jackson Laboratory. 5xFAD (APP and PS1 double-transgenic) 
mice co-express five familial AD mutations, namely, APP 
K670N/M671L (Swedish), I716V (Florida), V717I (London), 
PS1 M146L, and L286V, and have been shown to develop 
major pathological features of AD more rapidly than other 
transgenic AD-like animal models (Oakley et al., 2006). 
These animals present with increased amyloid plaque deposits 
and memory impairments in the Y and Morris water mazes 
at the ages of 2 and 4 months, respectively (Oakley et al., 
2006; Wang et al., 2014). All animals were fed, cared for, and 
handled in accordance with the Guide for the Care and Use 
of Laboratory Animals of the Xiamen University, and the 
Animal Ethics Committee Guidelines of the Animal Facility 
of the Zhongshan Hospital Xiamen University. The animals 
were acclimatized to the facilities for one week before the 
beginning of the treatment.
Drug Preparation and Reagents
Chinese medicines used for the concoction of BZD were supplied 
by the Zhongshan Hospital Xiamen University (Xiamen, 
China). Each herb was identified by the experts in the School 
of Pharmaceutical Sciences of Xiamen University. All voucher 
specimens were deposited at the Xiamen Botanical Garden (http://
sweetgum.nybg.org/science/ih/herbarium-details/?irn=249232) 
(Herbarium Code: XMBG) for future reference. BZD containing 
Radix Morindae Officinalis, Fructus Corni, Pheretima, Rhizoma 
Acori Tatarinowii, and Arisaema cum Bile (3:2:3:3:2) (see 
Table  1) was strictly decocted in accordance with the standards 
of Chinese medicine, and 3 concentrations (0.211 g/ml, 0.423 
g/ml, and 0.845 g/ml) were prepared using a heat cycle oven. 
Additionally, donepezil HCl (Aricept) was purchased from 
Eisai pharmaceutical Co., Ltd. Donepezil HCl was dissolved in 
a 1% solution of sodium carboxymethyl cellulose to obtain a 
concentration of 0.0325 mg/ml.
Antibodies against APP (369) and PS1-NTF (Ab14) were 
generated in-house (Thinakaran et al., 1996; Xu et al., 1997). 
Anti-BACE1 (3D5) antibody was kindly provided by Professor 
Robert Vassar (Northwestern University). Anti-β-actin antibody 
was purchased from ZEN bioscience, and anti-β-amyloid 
antibody was obtained from Abcam. Horseradish peroxidase 
labeled secondary goat anti-rat IgG antibody and goat anti-rabbit 
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IgG antibody were purchased from Pierce, and polyvinylidene 
difluoride (PVDF) membranes were purchased from Millipore. 
The protein loading marker was purchased from Fermentas, 
and the protease inhibitors were purchased from Roche. X-ray 
blue films were purchased from Kodak; BSA and TEMED were 
purchased from Sigma.
UhPlC-Ms
The major chemical constituents of BZD were profiled by 
ultra-high performance liquid chromatography (UHPLC) 
coupled with a high resolution electrospray ionization mass 
(HR-ESI-MS) detector. 10 mg lyophilized powder was dissolved 
in 1 mL of ultrapure water through ultrasonic method. The 
solution was filtered with 0.22 µm nylon filter membrane 
before injection into the UHPLC. The UHPLC separation was 
performed over a C18Kinetex column (100 × 2.1 mm i.d., 2.6 
µm, Phenomenex Inc., Torrance, USA) at 35 °C on the Thermo 
UltiMate 3000 LC system (Thermo Fisher Scientific, Bremen, 
Germany). The mobile phases were acetonitrile (A) and 0.1% 
formic acid with water (v/v) (B). Samples were eluted by 
gradients according to the elution program as follows: A from 
5% to 35% and B from 95% to 65% during 0–30 min, A from 35 
to 100% and B from 65 to 0% during 30–35 min, A and B were 
kept at 100 and 0% respectively during 35–45 min. The column 
was maintained at 35 °C and eluted at a flow rate of 0.3 mL/
min. The injected volume was 5 µL. A diode array detector with 
detection wavelength of 254 nm, and a high resolution ESI-MS 
detector were used to record the HPLC chromatograms. After 
UHPLC, samples were analyzed by MS spectra on a Thermo 
Q-Exactive system. The mass spectrometer with positive and 
negative ionizations was calibrated across m/z 100–1,500 using 
the manufacturer’s calibration standards mixture (caffeine, 
MRFA and Ultramark 1621 in anacetonitrile–methanol–water 
solution containing 1% acetic acid) allowing mass fluctuation 
of no more than 5 ppm in the external calibration mode. The 
ionization voltage was 3.5 kV, and the capillary temperature was 
set at 300 °C.
grouping and Treatment
The 5xFAD mice were randomly allocated to 5 groups, namely, 
control (5xFAD-Control), low-dose BZD (5xFAD-BZD-L), 
medium-dose BZD (5xFAD-BZD-M), high-dose BZD 
(5xFAD-BZD-H), and donepezil HCl (5xFAD-Donep) (n = 
8/group). Wild-type littermates, used as control mice, were 
randomly allocated to control (WT-Control), BZD (WT-BZD), 
and donepezil HCl (WT-Donep) groups (n = 8/group).
The clinical dosing of BZD and Donepezil HCl was 
determined in accordance with the Pharmacopoeia of the 
People’s Republic of China (2015). Mice in the control groups 
were administered 20 mL/(kg·d) double distilled water 
by gavage. The 5xFAD-Donep and WT-Donep mice were 
administered 20 mL/(kg·d) donepezil HCl at a dose of 0.65 
mg/(kg·d) and concentration of 0.0325 mg/mL. In addition, 
mice in the 5xFAD-BZD-L, 5xFAD-BZD-M, 5xFAD-BZD-M, 
and WT-BZD groups were orally administered 20 mL/(kg·d) 
BZD at doses of 4,225 g/(kg·d), 8,450 g/(kg·d), 16,900 g/(kg·d), 
and 16,900 g/(kg·d), respectively. All mice received treatment 
once daily by gavage for 12 weeks.
Behavioral Tests
The behavioral tests were initiated 10 days before the end of 
treatment (n = 8/group). On a normal test day, mice were allowed 
to adapt to the experimental environment for 30 min. Only one 
behavioral test was performed on each day. The order of the tests 
was organized so that easy to difficult tests could be performed 
in standard room-lighting conditions. Mazes were cleaned with 
75% alcohol immediately after the end of the test to minimize 
scent trails. Smart 3.0 software, a data collection system, and an 
overhead camera were used to monitor the activity of the mice.
The methods for the open field test and elevated plus maze 
used in our study have been described in detail elsewhere (Liu 
et al., 2014). For the open field test, mice were placed in an arena 
measuring 40 cm × 40 cm × 40 cm divided into 16 squares, for 
10 min. The total distance moved in the arena and the time spent 
in the central arena (central 4 squares) were analyzed for each 
mouse. For the elevated plus maze, the apparatus, which was 
elevated 40 cm above the ground, consisted of two opposing 
open arms (30 cm × 6 cm) and two opposing closed arms (30 cm   
6 cm × 15 cm) with an open roof. Each mouse was placed at the 
center of the maze facing an open arm. Then the experimenter 
exited the room, allowing the mouse to freely explore for 5 min. 
The frequencies of entries to the open arms, and the time spent 
in the open arms were recorded as an index of anxiety (higher 
index, lower anxiety).
TABle 1 | Information of components in BZD.
Chinese name Botanical name Common name Weight (g) Voucher numbers Part used
Ba Ji Tian Morinda officinalis How Radix Morindae Officinalis 15 180901 Root
Shan Zhu Yu Cornus officinalis Sieb. et Zucc. Asiatic Cornelian Cherry 
Fruit
10 180221 Matured sarcocarp
Shi Chang Pu Acorus tatarinowii Schott Grassleaf Sweetflag 
Rhizome
15 180901 Rhizome
Di Long Pheretima aspergillum (E. Perrier), Pheretima vulgaris 
Chen, Pheretima guillelmi (Michaelsen) or Pheretima 
Pectinifera Michaelsen
Earth Worm 15 181121 Dried body
Dan Nan Xing Arisaema erubescens (Wall.) Schott, Arisaema 
heterophyllum B1. or Arisaema amurense Maxim
Arisaema Cum Bile 10 171203 Powder
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Study has shown that (Ohno et al., 2004), the procedure for 
the Y Maze did not involve any training, reward, or punishment 
and allowed researchers to evaluate the rodents’ spontaneous 
spatial working memory. This test mostly assesses the function 
of the hippocampus. The Y maze comprised 3 symmetrical arms 
(30 cm × 6 cm × 15 cm) separated by 120 degrees. Every mouse 
was placed in the center of Y maze, with the head in the same 
direction, and was allowed to explore the arms freely for 5 min. 
The sequence and total number of arm entries were recorded. 
Data were analyzed using the percentage of alternation triplet, 
which was the number of triads containing entries into all 3 arms 
divided by the maximum possible number of alternations (the 
total number of arms entered - 2) × 100.
For the Morris water maze, the task was carried out in strict 
accordance with the protocol described by Geda (Vorhees and 
Williams, 2006). The maze consisted of a 1.2 m diameter, light 
blue, plastic, circular pool filled with water to a depth of 31 
cm with a temperature of 22 ± 1°C. The maze was divided 
into four quadrants (SW, SE, NE, and WN). A transparent 
platform was placed at the SW quadrant and was submerged 
~1 cm beneath the surface of the water. The test included two 
phases: spatial navigation training and probe experiments. 
During spatial navigation training, mice were first placed in 
one of the four starting locations facing the pool wall, and 
were allowed to swim until finding the platform in 60 s. The 
time that each mouse took to find the hidden platform was 
recorded. If the mice did not find the platform within 60 s, 
they were guided to the platform by the experimenter and 
were allowed to remain at the platform for 10 s. For the probe 
experiments, each trial was conducted when the animal’s 
latency to reach the platform tended to stabilize. The hidden 
platform was removed, and mice were placed in the pool at 
the opposite quadrant of the platform, and were allowed to 
swim freely for 60 s. Time spent in each quadrant, frequencies 
of crossings to the previous location of the target platform, 
and motion tracings were obtained using an automated video 
tracking software from Smart 3.0.
Collection of Brain Tissues
Experimental mice were sacrificed after completing the Morris 
water maze test. Briefly, the animals were anesthetized with 
1.5% pentobarbital sodium, perfused with phosphate buffered 
saline (PBS), and the brains were rapidly harvested on ice. Six 
mice were randomly selected from each group, and the left 
hemi-brains were fixed in fresh 4% paraformaldehyde and were 
used for immunohistochemistry analysis. The right hemi-brains 
were immediately frozen in liquid nitrogen for storage until 
homogenization for other biochemical assays.
Immunohistochemistry
Immunohistochemistry was performed as previously described 
(Hu et al., 2015) (n = 6/group). In summary, the brains were 
fixed for 48 h at 4°C in 4% paraformaldehyde and were then 
transferred to 30% sucrose for 2–3 days. O.C.T., a tissue freezing 
medium, was employed to freeze the brains and the tissue was 
then sectioned into 10-μm slices using a freezing microtome. 
Immunohistochemistry staining was used to determine Aβ 
plaques in the cortex and hippocampus. Anti-β-amyloid 
antibody (ab126649) was employed at a concentration of 1:500. 
The signal was revealed using the DAB chromogenic reagent kit. 
Light microscopy was used to capture the images. Densitometry 
analysis of the images was conducted using Image Pro Plus 6.0 
software.
Oxidative stress Assay
In summary, the hippocampal and cortical tissues were 
separated from the right hemi-brains (n = 6/group), 
homogenized in phosphate buffered saline (PBS) (mass 
ratio of 1:1) and were then divided into two parts, one for 
detecting SOD/MDA, and the other for detecting protein by 
western blot analysis. PBS (mass ratio of 1:10) was added to 
the homogenates and homogenization was repeated using a 
Polytron homogenizer. The homogenates were centrifuged 
at 3,000 r/min for 10 min at 4°C and the supernatants were 
collected. The SOD activity and MDA levels were determined 
according to the manufacturers’ instructions for Total 
Superoxide Dismutase (T-SOD) assay kit (Hydroxylamine 
method) or Malondialdehyde (MDA) assay kit (TBA method) 
from Nanjing Jiancheng Bioengineering Institute.
Western Blot
The other part of homogenates from hippocampal and 
cortical tissues (n = 6/group) was homogenized again in a 
buffer solution containing a protease inhibitor mix (Roche). 
Samples were centrifuged at 12,000g for 20 min at 4°C. The 
supernatant was collected and the proteins in the final elute 
were quantified using a BCA protein assay kit according to the 
manufacturer’s protocol. Equivalent amounts of protein were 
separated in 10% sodium dodecyl sulphate polyacrylamide 
gel (SDS-PAGE) and were then electrophoretically transferred 
to a PVDF membrane. The membranes were blocked with 
Tris-buffered saline containing 0.05% Tween-20 (TBST) and 
5% skimmed milk for 2 h. The membranes were then probed 
with primary antibodies (anti-APP, anti-PS1-NTF and anti-
BACE1) overnight at 4 °C, followed by incubation with 
horseradish peroxidase-linked secondary antibodies at room 
temperature (23 ± 2 °C) for 1 h. Signals were revealed using 
enhanced chemiluminescence western blotting detection 
reagents. Relative protein levels were normalized to β-actin. 
The intensity of the immunoreactive bands was quantified 
using Image J software.
statistical Analysis
Data have been expressed as mean ± standard deviation (SD). 
Statistical analyses were performed using GraphPad Prism 7.0 
(GraphPad Software Inc., La Jolla, United States). One-way 
analyses of variance (One-Way ANOVA) was used to compare 
the means of multiple groups. The least significant difference 
(LSD) method was selected for post hoc analysis. P < 0.05 was 
considered statistically significant.
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ResUlTs
Analysis of BZD
BZD was separated using the UHPLC-MS system and its 
chromatographic fingerprinting established. Comparing the 
retention time, UV and MS spectra with reference samples, the 
following twenty major components were identified: leucine 
(peak R1, Rt = 3.76 min), adenine (peak R2, Rt = 4.92 min), 
phenylalanine (peak R3, Rt = 5.27 min), 5-hydroxymethyl-2-
furaldehyde (peak C1, Rt = 6.23 min), tryptophan (peak R4, Rt = 
6.76 min), morroniside (peak C2, Rt = 7.96 min), asperuloside 
(peak M1, Rt = 8.82 min), loganin (peak C3, Rt = 9.41 min), 
sweroside (peak C4, Rt = 9.60 min), cornuside (peak C5, Rt = 
12.81 min), taurochenodeoxycholic acid (peak A1, Rt = 14.43 
min), glycohyodeoxycholic acid (peak A2, Rt = 14.85 min), 
2,4,5-trimethoxybenzaldehyde (peak G1, Rt = 16.31 min), 
β-asarone (peak G2, Rt = 16.99 min), cholic acid (peak A3, Rt 
= 20.21 min), rubiadin (peak M2, Rt = 20.86 min), physcion 
(peak M3, Rt = 21.31 min), hyodeoxycholic acid (peak A4, Rt = 
22.28 min), rubiadin-1-methyl ether (peak M4, Rt = 22.94 min), 
and 1,6-dihydroxy-2-methoxyanthraquinone (peak M5, Rt = 
24.21 min) as shown in Figures 1 and 2. Detailed information 
of BZD’s components identified by UHPLC is provided in the 
Supplementary Table.
BZD Improves learning and Memory 
Abilities and Alleviated Anxiety-Related 
Behaviors in 5xFAD Mice
To evaluate the impact of BZD treatment on locomotor activity and 
anxiety-related behaviors, we performed open field and elevated 
plus maze tests. In the open field test, there was no significant 
difference in the percentage of time spent in the center of the 
arena, or in the total distance traveled among groups (P > 0.05) 
(Figures 3A, B), indicating that locomotor activity of 6-month-
old 5xFAD mice is not altered. In the elevated plus maze, the 
5xFAD-Control mice spent greater time in the open arms and had 
a larger number of entries in the open arms (P < 0.01) (Figures 
3C, D) than the mice in the WT-Control group, suggesting that at 
6-months, 5xFAD mice showed attenuated anxiety in dangerous 
environments, with enhanced behavioral disinhibition (Olausson 
et al., 1999). BZD or donepezil HCl had no effect on anxiety in 
wild-type mice. Interestingly, we observed that the 5xFAD-
BZD-M, 5xFAD-BZD-H, and 5xFAD-Donep groups exhibited a 
marked decrease in the percentage of time spent in the open arms, 
and in the frequency of entries into the open arms when compared 
to the 5xFAD-control group (P < 0.05 or P < 0.01) (Figures 3C, 
D), confirming that medium and high doses of BZD attenuated 
the behavioral disinhibition of 5xFAD mice.
To investigate the effects of BZD on the pathological 
features related to learning and memory, we also tested the 
animals in the Y and Morris water mazes. In the Y maze, 
the 5xFAD-Control group showed a pronounced decrease 
in the percentage of triple alternations compared to the 
WT-Control group (P < 0.01) (Figure 4A), suggesting that 
spontaneous spatial working memory is impaired in 5xFAD 
mice. BZD and Donepezil increased the percentage of triple 
alternations in 5xFAD mice (P < 0.05) (Figure 4A), suggesting 
that medium and high doses of BZD improved spontaneous 
spatial working memory in 5xFAD mice. In the Morris water 
maze, as anticipated, we found that training shortened the 
escape latency time (ELT) of mice across groups (Figure 4B). 
On the sixth day of training, the mean ELT of the wild-type 
mice was under 20 s, while the 5xFAD mice presented with 
values of 20 s or higher. Nevertheless, both wild-type and 
5xFAD mice presented with stable values of ELT in the last 
two training days, suggesting that the probe experiment could 
be conducted on the seventh day. During the probe trials, the 
5xFAD-Control mice showed a dramatic decrease in spatial 
learning and memory compared to wild-type mice (P < 0.01 
or P < 0.001) (Figures 4C, D). Medium- and high-dose BZD 
and donepezil reduced this deficit, as demonstrated by the 
increased number of target (platform) crossing events and the 
percentage of time spent in the target quadrant, compared to 
the 5xFAD-control group (P < 0.05 or P < 0.01) (Figures 4C, 
D). Thus, Medium and high doses of BZD improved spatial 
learning and memory in 5xFAD mice.
BZD Reduces Aβ Deposition
Cumulative evidence suggests that aggregation of Aβ in the 
brain is a causative factor for AD pathogenesis. Aβ plaques were 
determined in the cortex and hippocampus of 5xFAD Mice and 
wild type littermates by immunostaining. The results showed that 
no positive staining was observed in the cortex or hippocampus 
of wild-type mice, whereas the 5xFAD mice presented with a 
high number of Aβ plaques (Figure 5A). Low-dose BZD did 
not affect the quantity of Aβ plaques (P > 0.05) (Figure 5B). 
However, donepezil HCl and medium- and high-dose BZD 
significantly reduced the burden of Aβ plaques in 5xFAD mice 
(P < 0.01) (Figure 5B).
BZD Modulates APP Processing
β-secretase and γ-secretase are two key elements of the 
amyloidogenic pathway of APP processing associated with 
the production of Aβ. To investigate whether BZD could 
affect APP processing, we checked the protein levels of APP, 
BACE1 and PS1-NTF in the lysates from hippocampal and 
cortical tissues of the experimental mice (5xFAD-Control, 
5xFAD-BZD-L, 5xFAD-BZD-M, 5xFAD-BZD-H, 5xFAD-
Donep, WT-Control, WT-BZD and WT-Donep) (Figure 6A). 
As expected, 5xFAD mice presented with significantly higher 
proteins levels of APP, BACE1 and PS1-NTF compared to the 
wild-type mice (Figures 6B–D). BZD and donepezil had no 
effect on APP protein levels (P > 0.05) (Figure 6B). High-dose 
BZD and donepezil decreased BACE1 protein levels in 5xFAD 
mice (P < 0.05); and medium and low-dose BZD had no effect 
(Figure 6C). PS1-NTF is the catalytic subunit of γ-secretase, 
an enzyme that plays an important role during APP processing. 
We found that Donepezil HCl and high but not medium or 
low doses of BZD, reduced the levels of PS1-NTF (P < 0.05) 
(Figure 6D). These results indicate that BZD may reduce Aβ 
level by modulating APP processing.
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FIgURe 1 | UHPLC-MS chemical fingerprint of BZD. Asperuloside (M1), rubiadin (M2), physcion (M3), rubiadin-1-methyl ether (M4), 1,6-dihydroxy-2-
methoxyanthraquinone (M5), 2,4,5-trimethoxybenzaldehyde (G1), β-asarone (G2), 5-hydroxymethyl-2-furaldehyde (C1), morroniside (C2), loganin (C3), sweroside 
(C4), cornuside (C5), taurochenodeoxycholic acid (A1), glycohyodeoxycholic acid (A2), cholic acid (A3), hyodeoxycholic acid (A4), leucine (R1), adenine (R2), 
phenylalanine (R3), and tryptophan (R4).
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BZD Decreases Oxidative Damage in the 
Cortex and hippocampus of 5xFAD Mice
Oxidative stress is implicated in the pathogenesis of AD. 
Recent studies have shown that increases in MDA content 
and the fluctuant activity of SOD are associated with the 
aggregation of Aβ plaques and AD (Zhou et al., 2014). To 
explore whether BZD could have an impact on MDA/SOD, 
we quantified MDA levels and SOD activity in homogenates 
of the cortical and hippocampal tissue samples. 5xFAD mice 
presented with higher levels of MDA and greater SOD activity 
than those in the WT-Control group (P < 0.01) (Figures 7A, 
B), suggesting that 5xFAD mice present with higher levels 
of free radicals and cellular damage. Interestingly, high- and 
medium-dose BZD and donepezil HCl reduced both MDA 
levels and SOD activity (P < 0.05) (Figures 7A, B). These 
results indicate that BZD decreases oxidative damage in the 
cortex and hippocampus of 5xFAD Mice.
DIsCUssION
In this study, we evaluated the potential impact of BZD, an 
alternative Chinese medicine formulation, on behavioral 
alterations in a transgenic mouse model of AD, including its 
key molecular hallmarks. We found that BZD exerted a dose-
dependent beneficial effect in 5xFAD mice. Medium and high 
doses of BZD not only ameliorated behaviors related to the 
disease, but also reduced the production and aggregation of 
Aβ plaques, probably by reducing the levels of BACE1 and PS1. 
FIgURe 2 | Chemical structure of the major identified components in BZD by UHPLC-MS: leucine, adenine, phenylalanine, tryptophan, 5-hydroxymethyl-
2-furaldehyde, asperuloside, morroniside, loganin, sweroside, cornuside, β-asarone, 2,4,5-trimethoxybenzaldehyde, taurochenodeoxycholic acid, rubiadin, 
1,6-dihydroxy-2-methoxyanthraquinone, glycohyodeoxycholic acid, cholic acid, hyodeoxycholic acid, physcion and rubiadin-1-methyl ether.
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We also identified a beneficial effect on oxidative stress (SOD/
MDA) in the hippocampi of 5xFAD mice. We suggest that BZD 
represent a therapeutic option for AD patients that is worth to be 
explored in randomized clinical studies.
According to the theory of TCM, AD results from 
insufficiency of kidney essence, intermingling of phlegm and 
blood, and fluid stasis (Peng and Huang, 2017). AD may, 
therefore, benefit from treatments invigorating the qi of the 
kidney, stimulating elimination of phlegm and promoting 
blood circulation to remove obstruction and dredge collaterals 
(Zhu and Hu, 2007). Based on this assumption, Morinda 
officinalis How. (Bajitian), Cornus officinalis Sieb. et Zucc. 
(Shanzhuyu), Earthworm (Dilong), Acori Tatarinowii 
Rhizoma (Shichangpu), and  Arisaema cum Bile (Dannanxing) 
were selected to compound the BZD formula. Bajitian is 
the sovereign drug that warms and recuperates the yang 
of the kidney, Shanzhuyu is the minister drug, nourishing 
and invigorating the yin and qi of the kidney, respectively, 
Shichangpu and Dannanxing are assistant drugs, that increase 
the elimination of phlegm, and Dilong is the envoy drug, which 
not only promotes blood circulation and removes obstruction 
in the collaterals, but also assists other drugs to penetrate into 
the diseased areas (Li et al., 2016; Peng and Huang, 2017). 
Therefore, BZD is consistent with the TCM prescription theory 
FIgURe 3 | BZD alleviates anxiety-related behaviors in 5xFAD mice. (A, B) Mice (5xFAD-Control, 5xFAD-BZD-L, 5xFAD-BZD-M, 5xFAD-BZD-H, 5xFAD-Donep, 
WT-Control, WT-BZD and WT-Donep) were analyzed for duration in the center (A) and total travel distance (B) in the open field test. Data are expressed as the 
mean ± SD from 8 mice per group, not significant, One-Way ANOVA. (C, D) Mice (5xFAD-Control, 5xFAD-BZD-L, 5xFAD-BZD-M, 5xFAD-BZD-H, 5xFAD-Donep, 
WT-Control, WT-BZD and WT-Donep) were analyzed for time in zone – open arms (C) and entries in zone – open arms (D) in elevated plus maze. Data are 
expressed as the mean ± SD from 8 mice per group. *P < 0.05, ** P < 0.01 compared with WT-Control group; #P < 0.05, ##P < 0.01 compared with 5xFAD-Control 
group, One-Way ANOVA.
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for AD, which aims to adjust the patients’ habitus including the 
syndromes of intermingled deficiency and excess, heat and cold, 
or phlegm and blood stasis. BZD may optimize the rapid aging 
internal environment and mobilize immune function, thereby 
extending life and improving intelligence. An increasing 
number of studies have suggested that single components 
of BZD are beneficial for AD. Oligosaccharides from Radix 
Morindae Officinalis improve memory function of AD animal 
models (Yang et al., 2018). Isolated compounds from Radix 
Morindae Officinalis ameliorate AD (Lee et al., 2017). Other 
pharmacological studies have also demonstrated that extracts 
of Radix Morindae Officinalis have anti-Alzheimer’s, anti-
fatigue, anti-aging, cardiovascular protective, anti-oxidative, 
immune-regulatory, and anti-inflammatory activities (Zhang 
et al., 2018). Studies using Fructus Corni have suggested 
a wide range of therapeutic properties for this compound, 
including neuroprotection, anti-amnesia, anti-aging, anti-
inflammation, analgesia, antioxidation, anti-osteoporosis, 
and immunoregulation (Huang et al., 2018a). Rhizoma Acori 
Tatarinowii reduces amyloid plaques and tau phosphorylation, 
and has anti-inflammatory effects (Deng et al., 2015; Song 
et al., 2018). Therefore, the anti-inflammatory and immunity-
enhancing effects may contribute to its therapeutic effects in 
AD. Arisaema cum Bile is useful for treating diseases associated 
with oxidative imbalance, such as AD, Parkinson’s disease, heart 
disease, rheumatoid arthritis and diabetes (Ahn et al., 2012). 
FIgURe 4 | BZD improves learning and memory abilities in 5xFAD mice. (A) Mice (5xFAD-Control, 5xFAD-BZD-L, 5xFAD-BZD-M, 5xFAD-BZD-H, 5xFAD-Donep, 
WT-Control, WT-BZD and WT-Donep) were analyzed for spontaneous alternation behavior by Y-maze tests. Data are expressed as the mean ± SD from 8 mice per 
group. **P < 0.01 compared with WT-Control group; #P < 0.05, ##P < 0.01 compared with 5xFAD-Control group, One-Way ANOVA. (B–D) Mice (5xFAD-Control, 
5xFAD-BZD-L, 5xFAD-BZD-M, 5xFAD-BZD-H, 5xFAD-Donep, WT-Control, WT-BZD and WT-Donep) were analyzed for spatial learning and memory in Morris water 
maze tests. Mice were analyzed for escape latency within a 6-day training period (B). On the 7th day, mice were assayed for the number of crossings over the target 
platform region (C) and time spent in target quadrant (D). Data are expressed as the mean ± SD from 8 mice per group. **P < 0.01, ***P < 0.001 compared with 
WT-Control group; #P < 0.05, ##P < 0.01 compared with 5xFAD-Control group, One-Way ANOVA.
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Earthworm may have immune regulatory, anti-inflammatory, 
anti-bacterial and anti-oxidative properties, which are closely 
related to AD (Huang et al., 2018b). BZD therapeutic effects are 
likely to benefit from the synergistic effects of these compounds 
when administered concomitantly. However, empirical 
evidence supporting this hypothesis is still scarce.
In this study, BZD was separated using the UHPLC-MS 
system and 20 major chemical components were identified. 
Taurochenodeoxycholic acid, as a signaling molecule, shows 
obvious anti-inflammatory and immune regulation properties. 
Taurochenodeoxycholic acid plays a role in the PKC/JNK signaling 
pathway, and may be a latent effective pharmaceutical product for 
FIgURe 5 | BZD Reduces Aβ Deposition. (A) Immunohistochemistry analysis of Aβ plaques in the cortex and hippocampus of 5xFAD Mice (5xFAD-Control, 
5xFAD-BZD-L, 5xFAD-BZD-M, 5xFAD-BZD-H and 5xFAD-Donep) and wild type (WT) littermates. Representative images of Aβ plaques; Scale bar, 150 μm. 
(B) Quantification of Aβ plaques in A. Data are expressed as the mean ± SD from 6 mice per group. ##P < 0.01 compared with 5xFAD-Control group, One-Way 
ANOVA.
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apoptosis- or age-related diseases (Wang et al., 2016). Tryptophan 
is converted via the 5-hydroxyindole pathway to serotonin, a 
neurotransmitter in the brain, paracrine and endocrine signal 
in the gut, and a paracrine signal and vasoconstrictor released 
by platelets. It is also converted by endocrine and other cells 
via serotonin to the hormone melatonin, which may improve 
mood and sleep (Fernstrom, 2016). Rubiadin-1-methyl ether 
may be a therapeutic candidate for bone diseases characterized 
by enhanced bone resorption (He et al., 2018a). Asperuloside 
and sweroside both can exert an anti-inflammatory effect via 
suppression of the NF-κB signaling pathways in LPS-induced 
RAW 264.7 cells (He et al., 2018b; Wang et al., 2019). Rubiadin, 
a dihydroxy anthraquinone, isolated from alcoholic extract of 
Rubia cordifolia, possesses potent antioxidant property (Tripathi 
et al., 1997). Hyodeoxycholic acid protects the neurovascular unit 
against oxygen-glucose deprivation and reoxygenation-induced 
injury in vitro (Li et al., 2019). 2,4,5-trimethoxybenzaldehyde, a 
bitter principle in plants, suppresses adipogenesis through the 
regulation of ERK1 (Wang and Kuo, 2014). Physcion blocks cell 
cycle and induces apoptosis in human B cell precursor acute 
lymphoblastic leukemia cells by downregulating HOXA5 (Gao 
et al., 2017). Morroniside protects against cerebral ischemia/
reperfusion injury by inhibiting neuron apoptosis and MMP2/9 
expression (Zeng et al., 2018). Loganin exerts sedative and 
hypnotic effects via modulation of the serotonergic system and 
GABAergic neurons (Shi et al., 2019). Cornuside attenuates 
apoptosis and ameliorates mitochondrial energy metabolism 
in rat cortical neurons (Jiang et al., 2009; Jiang et al., 2014). 
FIgURe 6 | BZD Modulates APP Processing. (A) Equal protein quantities of lysates from hippocampal and cortical tissues of mice (5xFAD-Control, 5xFAD-BZD-L, 
5xFAD-BZD-M, 5xFAD-BZD-H, 5xFAD-Donep, WT-Control, WT-BZD and WT-Donep) were subjected to western blot with antibodies against APP, BACE1, PS1-NTF, 
and β-actin. APP (B), BACE1 (C) and PS1-NTF (D) protein intensities were quantified by densitometry, and normalized to respective β-actin levels. Data are expressed 
as the mean ± SD from 6 mice per group. **P < 0.01 compared with WT-Control group; #P < 0.05 compared with 5xFAD-Control group, One-Way ANOVA.
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Cholic acid can be used as a treatment for cerebrotendinous 
xanthomatosis in adults (Mandia et al., 2019). 5-hydroxymethyl-
2-furaldehyde (5-HMF) may block scopolamine-induced 
learning deficit and enhance cognitive function via the activation 
of NMDA receptor signaling, including CaMKII and ERK, and 
would be an effective candidate against cognitive disorders, such 
as Alzheimer’s disease (Lee et al., 2015). Leucine-rich repeat 
kinase 2 is associated with activation of the paraventricular 
nucleus of the hypothalamus and stress-related gastrointestinal 
dysmotility (Maekawa  et  al.,  2019). All of these chemical 
components have anti-aging, anti-inflammatory, anti-oxidative, 
immune-regulatory, anti-tumor, and neuroregulatory properties, 
among others.
AD is characterized by memory loss and cognitive impairment, 
and various neuropsychiatric symptoms including depression, 
anxiety, hallucination, irritability, indifference and 
disinhibition (Geda et al., 2013). Here the potential effects 
of BZD on locomotor activity and anxiety were assessed by 
the open field and elevated plus maze tests; while the effect of 
BZD on learning and memory was assessed using the Y and 
Morris water maze tests. The open field test reflects locomotor 
activity, spontaneous exploration, and anxiety levels of mice 
in a novel environment (typically, the greater is the time 
spent in the central arena, the less is the anxiety; greater 
distances traveled are associated with greater locomotor 
activity) (Heredia et al., 2014). In this cohort, 6-month-old 
5xFAD mice and the wild-type littermates did not differ with 
respect to general locomotor activity. BZD had no effect on 
the locomotor activity of 5xFAD mice.
To further assess the effects o on anxiety levels, we used the 
elevated plus maze. Since mice have an innate fear of elevated 
open places, when allowed to freely explore the maze, they 
typically enter less and spend shorter time in the open arms 
as compared to the closed arms of the maze (Walf and Frye, 
2007). Therefore, a greater number of entries and time spent 
in the open arms indicate low anxiety levels and behavioral 
disinhibition (Walf and Frye, 2007). Moreover, 6-month-
old 5xFAD mice presented with lower anxiety in dangerous 
environments, indicating a tendency toward disinhibition. This 
result concurs with that of previous reports suggesting that 
approximately 35% of mild AD patient’s exhibit disinhibition, 
which manifests as impulsive behavior, talking to strangers 
like acquaintances, ignoring dangers, and excessive euphoria 
(Olausson et al., 1999; Starkstein et al., 2004). Importantly, 
medium and high doses of BZD attenuated this behavioral 
alteration by increasing vigilance and attenuating behavioral 
disinhibition in the 5xFAD mice.
The Y maze is typically used to assess spontaneous spatial 
working memory in rodents (Ohno et al., 2004) by analyzing the 
percentage of alternation triplet (the higher the percentage of 
alternation triplets, the better the spontaneous spatial working 
memory). In our study, 5xFAD mice exhibited impaired 
spontaneous spatial working memory. We found that medium 
and high doses of BZD improved memory impairments in 
5xFAD mice, as shown by an increase in the percentage of 
alternation triplets. The Morris water maze is one of the classic 
behavioral tests for spatial learning and memory capacity in 
rodents (Barnhart et al., 2015). The escape latency time acquired 
after spatial navigation training reflects the learning capacity. 
A short ELT indicates strong learning capacity; conversely, 
a long ELT indicates poor learning capacity. As anticipated, 
5xFAD mice showed marked impairment in spatial learning and 
FIgURe 7 | BZD Decreases MDA Levels and SOD Activity in the Cortex and Hippocampus of 5xFAD Mice. (A) Activities of SOD were measured in the cortical and 
hippocampal tissue samples of mice (5xFAD-Control, 5xFAD-BZD-L, 5xFAD-BZD-M, 5xFAD-BZD-H, 5xFAD-Donep, WT-Control, WT-BZD and WT-Donep). Data 
are expressed as the mean ± SD from 6 mice per group. **P < 0.01 compared with WT-Control group; ##P < 0.05, ##P < 0.01 compared with 5xFAD-Control group, 
One-Way ANOVA. (B) MDA levels were measured in the cortical and hippocampal tissue samples of mice (5xFAD-Control, 5xFAD-BZD-L, 5xFAD-BZD-M, 5xFAD-
BZD-H, 5xFAD-Donep, WT-Control, WT-BZD and WT-Donep). Data are expressed as the mean ± SD from 6 mice per group. **P < 0.01 compared with WT-Control 
group; ##P < 0.01 compared with 5xFAD-Control group, One-Way ANOVA.
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memory. However, medium and high doses of BZD significantly 
ameliorated this deficit.
One of the most critical pathological features of AD is 
accumulation of Aβ, which is derived from APP through 
sequential cleavage by β-secretase and γ-secretase (Jiang et  al., 
2014). Here we showed that Aβ plaques were significantly 
reduced in the cortex and hippocampus of 5xFAD mice when 
treated with medium- and high-dose BZD, as well as donepezil 
HCl. Further, we showed that high-dose BZD decreased BACE1 
and PS1 protein levels in 5xFAD mice, indicating that reduction 
of Aβ may be due to altered APP processing.
Increased activity of SOD typically indicates enhanced 
protection against oxidative stress and damage. However, at 
early stages of the inflammatory reaction (compensation stage), 
SOD activity is known to increase owing to the overproduction 
of free radicals. As anticipated, we found increased levels of 
MDA and higher SOD activity in the 5xFAD mice, suggesting 
that although these animals may suffer from damage caused by 
oxidative stress, they are likely to remain in the compensatory 
period. Interestingly, medium and high doses of BZD attenuated 
both MDA levels and SOD activity, suggesting beneficial effects 
on hippocampal oxidative stress.
Our results show the potential preventive effects of BZD during 
an early stage of AD (6-month-old 5xFAD mice), which may not 
be generalized to include later stages of the disease, where the 
pathology is already fully established and is more severe. Further 
studies evaluating the extent of benefits of BZD in more advanced 
stages of the disease are warranted, to fully unravel its therapeutic 
potential in AD. In addition, future studies are required to directly 
compare different therapeutic schemes that vary in the timing of 
administration, and to determine the best time-window for BZD 
administration. This knowledge may aid in designing future 
clinical studies to evaluate whether BZD is a viable treatment 
option in AD.
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